This week, the product liability and MDL attorneys at Zoll & Kranz, LLC (ZK) filed our first lawsuit against the manufacturer of Taxotere by filing a Complaint in the Northern District of Illinois. The Complaint alleges that the chemotherapy drug Taxotere (docetaxel) caused serious harm to a female breast cancer survivor, including permanent and disfiguring alopecia (hair loss). It also alleges that Taxotere’s manufacturer, a large multi-national pharmaceutical company, knew of the risk of permanent and irreversible hair loss in chemotherapy patients taking Taxotere, but failed to adequately warn U.S. doctors and patients of this risk and misled consumers and the medical community about the safety and effectiveness of the drug.
Although temporary hair loss is a common side effect of chemotherapy treatment, we continue to investigate the potential connection between the chemotherapy drug, Taxotere, and permanent hair loss in women being treated for breast cancer. Studies have shown the devastating effect even temporary hair loss has on women, and some breast cancer survivors are finding themselves permanently suffering this condition, despite being in remission from their cancer.
Zoll & Kranz, LLC attorneys are advocates for these breast cancer patients and appreciate the relationship patients establish with their oncologists. We believe patients and their doctors were deprived of the right to make fully informed treatment decisions. We invite you to visit our webpage to read more about the unwarned risks and the Taxotere lawsuit that we continue to investigate.
If you believe you or a loved one may have been affected, we offer a free case evaluation. You can reach our caring and experienced Taxotere lawsuit team through our form on the webpage linked here, or call toll-free at 888-841-9623.